First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer

  • Authors:
    • Erlinda M. Gordon
    • Gerardo H. Cornelio
    • Conrado C. Lorenzo
    • John P. Levy
    • Rebecca A. Reed
    • Liqiong Liu
    • Frederick L. Hall
  • View Affiliations

  • Published online on: January 1, 2004     https://doi.org/10.3892/ijo.24.1.177
  • Pages: 177-185
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metastatic or non-resectable (stage IV) pancreatic cancer has a rapidly fatal outcome (median survival: 3-6 months), thus making gene therapy a viable therapeutic option. The objectives of the clinical studies are to evaluate the safety/toxicity and potential anti-tumor response/efficacy of intravenous (i.v.) infusions of a ‘pathotropic’ retroviral vector bearing a cytocidal gene construct (Rexin-G) as a gene transfer intervention for stage IV pancreatic cancer. An intra-patient dose escalation regimen was used wherein increasing doses of Rexin-G were given i.v. daily for 8-10 days. Completion of this regimen was followed by a one-week evaluation period for toxicity, after which, the maximum tolerated dose of Rexin-G was administered for another 8-10 days. In a second protocol, i.v. Rexin-G was administered frontline for 6 days followed by 8 doses of weekly gemcitabine. The NIH Common Toxicity Criteria Vs.2 was used to assess toxicity, and the NCI-RECIST criteria and tumor volume measurements were used to evaluate potential anti-tumor responses. We report the results of the first 3 patients that participated in the studies. Rexin-G arrested tumor growth in 3 of 3 patients without experiencing dose-limiting toxicity. No bone marrow suppression, significant alterations in liver and kidney function, nausea and vomiting, mucositis or hair loss were observed. Two patients are alive with stable disease ≈5 and 14 months from diagnosis, and 1 patient is alive with progressive disease 20 months from diagnosis. The encouraging results of this first clinical experience will guide the design and planning of phase I/II clinical trials to establish the safety and efficacy of Rexin-G as the first targeted injectable gene therapy vector for stage IV pancreatic cancer.

Related Articles

Journal Cover

January 2004
Volume 24 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gordon, E.M., Cornelio, G.H., Lorenzo, C.C., Levy, J.P., Reed, R.A., Liu, L., & Hall, F.L. (2004). First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. International Journal of Oncology, 24, 177-185. https://doi.org/10.3892/ijo.24.1.177
MLA
Gordon, E. M., Cornelio, G. H., Lorenzo, C. C., Levy, J. P., Reed, R. A., Liu, L., Hall, F. L."First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer". International Journal of Oncology 24.1 (2004): 177-185.
Chicago
Gordon, E. M., Cornelio, G. H., Lorenzo, C. C., Levy, J. P., Reed, R. A., Liu, L., Hall, F. L."First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer". International Journal of Oncology 24, no. 1 (2004): 177-185. https://doi.org/10.3892/ijo.24.1.177